Centurium Capital is weighing the sale of its stake in Taibang Biologic Group in a deal that could value the Chinese biopharmaceutical company at around $6bn, according to people familiar with the matter cited by Bloomberg.

The Beijing-based private equity firm has approached potential buyers, including state-owned entities, though deliberations remain ongoing and no decision has been finalised.

Taibang, established in 2002 and formerly known as China Biologic Products Holdings, specialises in plasma-derived therapies including albumin, human immunoglobulin, and coagulation factors. The company was listed on Nasdaq until 2021, when Centurium led a $4.8bn take-private alongside Citic Capital, Hillhouse, and Temasek.

The group subsequently explored a Hong Kong listing but instead raised $300m in 2022 from new investors including Abu Dhabi Investment Authority subsidiary Platinum Orchid and Singapore sovereign wealth fund GIC.

Centurium declined to comment on the possible transaction, while Taibang did not respond to inquiries.

If completed, the sale would mark one of the largest private equity exits in China’s healthcare sector this year, underlining continued investor interest in plasma-based therapies despite market volatility.

If you think we missed any important news, please do not hesitate to contact us at news@pe-insights.com.

Can`t stop reading? Read more.